Cook Regentec spinout Sexton Biotechnologies said today that it raised $5 million for the cell and gene therapy bioproduction tools it’s developing.
The company is Cook’s first to pick up outside investment capital and spin out as an independent biotechnology company, according to a news release. Sexton is made up of a 17-person team from Cook Regentec that’s developed, incubated and commercialized products since 2015.
Get the full story at our sister site, Drug Delivery Business News.